This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Sequester Cuts Threaten Life-Saving HIV/AIDS Care And Prevention Services

SAN FRANCISCO, March 4, 2013 /PRNewswire-USNewswire/ -- The sequester, with its devastating cuts to virtually every line item in the federal budget, is now forcing our nation to take a troubling step backward in the fight against HIV/AIDS. The cuts mean fewer chances for people to learn their HIV status, get the medical care they need to stay healthy, and avoid passing the virus on to others. It is now incumbent upon Congress to restore these funds as quickly as possible to minimize the harmful impacts to our country's health.

"The cuts to HIV health, prevention, housing, and research programs will have a damaging and destabilizing impact on the lives of people living with HIV/AIDS," said Neil Giuliano, CEO of San Francisco AIDS Foundation. "This totally avoidable wound to the nation's economy moves us backward at a time when we have the tools to dramatically change the trajectory of the HIV/AIDS epidemic. Unfortunately, our federal leaders have chosen a path that will result in worse health outcomes for hundreds of thousands of people across the country."

San Francisco AIDS Foundation, together with the HIV/AIDS advocacy community, other health groups, and the nation's governors and mayors, is calling on Congress to negotiate a resolution so that the full impact of these massive cuts is never felt and essential services continue to help those most in need.

The sequester requires an automatic 5% across-the-board funding cut. The AIDS Drug Assistance Program (ADAP) faces a cut that will result in 7,400 people living with HIV losing access to life-saving medications. The Centers for Disease Control and Prevention (CDC) estimates that 424,000 fewer HIV tests will be provided nationwide, and 49,300 fewer tests in California. The state of California will see a $12.4 million cut to its substance-use treatment grant, resulting in 9,400 fewer treatment slots. The federal government is now distributing only partial Ryan White Program funding to the most heavily impacted jurisdictions in the United States; the remaining funds await the final federal budget negotiations.

"These cuts have real consequences and they are taking an immediate toll on some of our most vulnerable citizens," said Ernest Hopkins, director of legislative affairs at San Francisco AIDS Foundation. "The political gamesmanship we've witnessed in Washington is poor policy and puts the health of individuals and entire communities at risk. We are now working to ensure that the cuts to the federal budget do the least harm to HIV prevention efforts and patient care."

About San Francisco AIDS Foundation No city experienced epidemic levels of HIV faster than San Francisco. At San Francisco AIDS Foundation, we work to end the epidemic where it first took hold, and eventually everywhere. Established in 1982, our mission is the radical reduction of new infections in San Francisco. Through education, advocacy, and direct services for prevention and care, we are confronting HIV in communities most vulnerable to the disease. We refuse to accept that HIV transmission is inevitable.

Contact: Ryan McKeel(415) 487-3071 rmckeel@sfaf.org

SOURCE San Francisco AIDS Foundation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs